IPOs get back in­to gear with fil­ings from Lian­Bio and Xilio, and Cor­moran­t's SPAC has a deal

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

As the fourth quar­ter gets un­der­way, the biotech IPO mar­ket is revving its en­gines back up.

Two more com­pa­nies filed to make their Nas­daq de­buts Fri­day, Xilio Ther­a­peu­tics and Lian­Bio, each pen­cil­ing in the stan­dard $100 mil­lion es­ti­mate. There was al­so a SPAC merg­er that land­ed ear­ly Mon­day morn­ing, as a blank check com­pa­ny from Cor­morant As­set Man­age­ment re­verse merged with Swiss biotech Moon­Lake Im­munother­a­peu­tics in a $230 mil­lion deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER